8-K: Avidity Stockholders Approve Novartis Merger, Spin-Off

Avidity Biosciences stockholders overwhelmingly approved the merger agreement with Novartis AG and the separation agreement for Atrium Therapeutics, satisfying a key transaction condition.

Summary

• A special meeting of stockholders was held virtually via live webcast on February 26, 2026.
• Stockholders voted in favor of adopting the Agreement and Plan of Merger with Novartis AG and the Separation and Distribution Agreement for Bryce Therapeutics, Inc. (now Atrium Therapeutics, Inc.).
• As of the record date, January 29, 2026, 154,740,172 shares of common stock were eligible to be voted.
• At the meeting, 123,715,570 shares, or approximately 79.95% of all outstanding shares, were present either in person or by proxy.
• The Transactions Proposal was approved with 123,351,048 votes For, 8,090 Against, and 60,331 Abstentions.
• The Non-Binding Merger-Related Compensation Proposal was also approved with 101,383,553 votes For, 21,654,186 Against, and 381,730 Abstentions.
• The Adjournment Proposal was not voted upon as there were sufficient votes to approve the Transactions Proposal.
• The approval of the Transactions Proposal satisfies the stockholder vote condition required for the consummation of the transactions.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as the successful stockholder vote removes a significant hurdle for the planned merger and spin-off, indicating progress towards strategic objectives.

Positives

• Stockholders approved the Merger Agreement with Novartis AG and the Separation Agreement, fulfilling a critical condition for the transactions to proceed.
• The high percentage of 'For' votes (123,351,048) for the Transactions Proposal indicates strong shareholder support for the strategic direction.
• The Adjournment Proposal was not needed, indicating efficient resolution of the primary agenda.

Future Outlook

The approval of the Transactions Proposal by stockholders satisfies a key condition for the consummation of the merger with Novartis AG and the separation of Atrium Therapeutics, Inc., indicating the transactions are on track to proceed.

Industry Context

StockSavvy.ai notes that this stockholder approval is a standard procedural step in large-scale pharmaceutical mergers and spin-offs, reflecting the ongoing consolidation and strategic restructuring within the biotechnology and pharmaceutical sectors. Such transactions aim to streamline operations, focus core competencies, and unlock shareholder value.

Stakeholder Impact

• Shareholders: The approval directly impacts shareholders by moving forward with the merger and spin-off, potentially altering their investment structure and future returns.

Next Steps

• Consummation of the transactions contemplated by the Merger Agreement and Separation Agreement, now that the stockholder vote condition has been satisfied.

Key Dates

Keywords

Avidity Biosciences, Novartis, Merger Agreement, Separation Agreement, Stockholder Vote, Corporate Action, Atrium Therapeutics, 8-K Filing, Biotechnology, Acquisition